eXciteOSA
Commercial- Indications
- Sleep disordered breathing, Obstructive sleep apnea, Snoring
Company intelligence / Profile preview
eXciteOSA®, the company's lead product, has treated over 10,000 patients since its commercial launch in 2021. It is FDA-authorized as the first daytime therapy for snoring and mild obstructive sleep apnea. Clinical trials are ongoing to further validate efficacy; published data show significant improvement in airway patency and reduction in symptoms with daily use. The product has achieved major commercial milestones including large-scale orders from home medical equipment providers and expanded Medicaid coverage in several US states.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Signifier Medical Technologies.